In the primary and follow-up analyses of the phase 3 CASTOR study in patients with relapsed or refractory multiple myeloma (RRMM), a regimen of daratumumab, bortezomib, and dexamethasone significantly prolonged progression-free survival (PFS) and induced higher rates of deeper responses than bortezomib and dexamethasone alone.1-3 This publication summarises data from an update of the CASTOR study after a median follow-up of 40 months3 and demonstrated that a regimen of daratumumab, bortezomib, and dexamethasone maintained significant benefits in RRMM patients and with a consistent safety profile.
Download PDF